Overview
Aylin Erol practices practicing medicine in Dokuz Eylul, Turkey.
Her clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Non-Muscle Invasive Bladder Cancer.
She is actively involved in clinical research, co-authoring 11 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Aylin Erol
Is Aylin Erol a top-rated expert for Neuroblastoma?
MediFind is an objective health platform that identifies experts based on real-world data. Aylin Erol is classified as an Experienced expert for Neuroblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Aylin Erol participate in research or clinical trials?
Yes. Aylin Erol has published 11 articles and abstracts on conditions like Neuroblastoma. You can view a list of Aylin Erol's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Embryonal Tumor with Multilayered Rosettes
- Gliomatosis CerebriMs. Erol isExperienced. Learn about Gliomatosis Cerebri.
- NeuroblastomaMs. Erol isExperienced. Learn about Neuroblastoma.
- Non-Muscle Invasive Bladder CancerMs. Erol isExperienced. Learn about Non-Muscle Invasive Bladder Cancer.